Trial reportPediatric nephrology (Berlin, Germany)2016
Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial.
Trial report in Pediatric nephrology (Berlin, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Corticosteroid therapy for nephrotic syndrome in children.The Cochrane database of systematic reviews · 2024Pooled it
- Corticosteroid therapy for nephrotic syndrome in children.The Cochrane database of systematic reviews · 2020Pooled it
- Efficacy of body weight vs body surface area-based prednisolone regimen in nephrotic syndrome.Clinical and experimental nephrology · 2020Trial
- Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: a prospective randomized pilot study.European journal of pediatrics · 2020Trial
- Nephrotic Syndrome: Current Management.Indian journal of pediatrics · 2026Review
- Aligning Practice With Guidelines: A Canadian National Survey and Canadian Society of Nephrology Commentary on the 2025 KDIGO Pediatric Nephrotic Syndrome Recommendations.Canadian journal of kidney health and disease · 2026Article
- Growth Hormone Dosing Estimations Based on Body Weight Versus Body Surface AreaJournal of clinical research in pediatric endocrinology · 2023Article
- Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2022Review
- Steroid Sensitive Nephrotic Syndrome: Revised Guidelines.Indian pediatrics · 2021Article
- Treatment of idiopathic nephrotic syndrome with two steroid dosing regimens - one-year observational study.Central-European journal of immunology · 2021Article
- Equations to estimate prednisone dose using body weight.Pediatric nephrology (Berlin, Germany) · 2019Article
- Should we stop dosing steroids per body surface area for nephrotics?Pediatric nephrology (Berlin, Germany) · 2016Article
- Weight-based dosing in medication use: what should we know?Patient preference and adherence · 2016Review
- Effectiveness of a Low Dose Prednisolone Regimen for Treatment of Relapses in Children with Steroid Sensitive Nephrotic Syndrome.Indian journal of nephrologyArticle
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBody surface area (BSA)-based prednisolone dosing for childhood nephrotic syndrome (NS) leads to higher cumulative prednisolone doses than body weight (BW)-based dosing. The clinical effects of this higher dosage have not been evaluated in prospective studies.
methodsThis parallel-group open-label randomized clinical trial enrolled 100 children with idiopathic NS, to receive BW-based (n = 50) or BSA-based (n = 50) prednisolone dosing by block randomization in a 1:1 ratio. The time taken for remission, relapse rate per 6 months, and adverse effects of steroids were analyzed in both groups.
resultsThere was no significant difference in the time taken for remission in the BW group versus the BSA group (median (IQR) 7 (4.5-9) versus 5.5 (4-8) days; p = 0.082); similar results were observed on subgroup analysis in new-onset and infrequently-relapsing NS (IFRNS). The cumulative prednisolone dosage during the enrolment episode was higher in the BSA group. The incidence of hypertension was higher (p = 0.048) in the BSA group on per-protocol analysis. The relapse rates in the two groups per 6 months on follow-up were comparable.
conclusionsClinical outcomes with BW-based dosing are equivalent to BSA dosing-related outcomes, although cumulative prednisolone doses are lower in the former. The practice of BW-based calculations for prescribing prednisolone in NS is a reasonable approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.